Clinical evaluation of Cefditoren pivoxil (ME1207) in the treatment of oral infections.

概要

論文の詳細を見る
The clinical efficacy and safety of ME1207 as a treatment for odontogenic infections such as periodontitis, pericoronitis and osteitis was evaluated in 9 institutions. The results were as follows : 1) Clinical efficacy : The overall clinical efficacy rate determined according to the standards established by the Committee was 84.0 %. By disease, the efficacy rates were 76.5 %, 76.9 % and 97.1 % for periodontitis, pericoronitis and osteitis, respectively. The overall efficacy rate assessed by the doctors in charge was 83.0 % and the efficacy rates by diagnosis were 76.5 %, 88.5 % and 85.3 % for periodontitis, pericoronitis and osteitis, respectively. 2) Bacteriological response : The MIC50 and MIC90 of ME1207 against 100 clinically isolated strains were 0.10 and 0.78 μg/ml, respectively. For 53 aerobes strains, the MIC50 and MIC90 were 0.10 and 0.20 μg/ml. Against 36 strains of oral streptococci, the range of MIC were from ≤0.025 to 0.20 μg/ml. The MIC50 and MIC90 against 47 strains of anaerobes were 0.10 and 0.78 μg/ml, respectively. The eradication rate against infecting organisms from 46 patients were 73.9 % as judged by old criteria. 3) Safety : Mild side effects occurred in 6 (6.3%) of the 96 patients treated and slightly abnormal laboratory findings were found in 2 (3.1%) of 64 patients examined.
日本歯科薬物療法学会の論文